ReviewDiscover mental health2025
An overview of oxytocin integrative mechanisms in autism spectrum disorder.
Review in Discover mental health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autism Spectrum Disorder (ASD) is a multifaceted neurodevelopmental condition characterized by impairments in social interaction, communication, and repetitive behaviors. Its etiology involves a complex interplay of genetic, environmental, and neurobiological factors. The oxytocin (OT) system, central to social behavior and emotional regulation, has emerged as a key area of interest in ASD research. This review synthesizes current evidence, highlighting that dysregulation of OT and its receptor (OTR) signaling, often characterized by lower baseline OT levels and altered OTR expression due to genetic and epigenetic factors, contributes to the social and behavioral deficits observed in ASD. While aberrant OT/OTR signaling presents a potential target for therapeutic intervention, the narrative has evolved beyond simple peptide replacement. Critical analysis reveals that intranasal OT administration, as a standalone treatment, yields inconsistent results due to its non-specific delivery and inability to address core circuit-level dysfunctions established during neurodevelopment. Promising future avenues include the development of selective OTR agonists, epigenetic modulation to correct OTR expression, and the use of OT as a targeted adjunct to enhance behavioral therapy efficacy. This paper provides a comprehensive and critical overview of the integrative mechanisms linking OT/OTR signaling to ASD, evaluates the therapeutic potential of correcting this pathway, and emphasizes the necessity for personalized, biomarker-driven approaches to improve social cognition and neural connectivity in individuals with ASD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.